|
evilbastard posted:These systems rely heavily on patents expiring, so the threat for patent extension, or "evergreening" (where a drug is re-patented through a minor change in delivery method, or the addition of a new chemical that doesn't substantially change the method of action) would cripple both systems and enable pharmaceutical companies to sell at full price. I don't see how this follows. If the original drug in its original delivery method is off patent, why can't a generic drug maker make that?
|
# ¿ Jun 13, 2015 01:21 |
|
|
# ¿ May 16, 2024 23:21 |